Navigation Links
Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting
Date:10/16/2009

e polyarticular juvenile idiopathic arthritis in children ages 2 and older.
  • ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with psoriatic arthritis. ENBREL can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.
  • ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.
  • ENBREL is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
  • IMPORTANT SAFETY INFORMATION

    What is the most important information I should know about ENBREL?

    ENBREL is a medicine that affects your immune system. ENBREL can lower the ability of your immune system to fight infections. Serious infections have happened in patients taking ENBREL. These infections include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some patients have died from these infections. Your doctor should test you for TB before you take ENBREL and monitor you closely for TB while on ENBREL.

    Before starting ENBREL, tell your doctor if you:

    • Think you have, are being treated for, have signs of, or are prone to infection. You should not start taking ENBREL if you have any kind of infection.
    • Have any open cuts or sores
    • Have diabetes or an immune system problem
    • Have TB or have been in close contact with someone who has had TB
    • Were born in, lived in, or traveled to countries where there is more risk for getting TB. Ask your doctor if you are not sure.
    • Live or have lived in certain parts of the country (such as, the Ohio and Mississippi River valleys, or the Southwest) where there is a greater risk for certain
      '/>"/>

    SOURCE Amgen
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine news :

    1. Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis
    2. Plastic Surgery 2009 News Briefs - Selected Research to be Presented on Tuesday, October 27
    3. Plastic Surgery 2009 News Briefs - Selected Research to be Presented on Monday, October 26
    4. Plastic Surgery 2009 News Briefs - Select Research to be Presented on Sunday, October 25
    5. Plastic Surgery 2009 News Briefs -- Research To Be Presented on Saturday, October 24
    6. Novel Information about Vulnerable Coronary Artery Plaque to be Presented at Transcatheter Cardiovascular Therapeutics (TCT) 2009
    7. PolyOne Presented with Frost & Sullivan Medical Product Award
    8. CRF announces featured clinical trials to be presented at TCT 2009 in San Francisco
    9. Kuvan and Naglazyme Data to Be Presented at the 11th Annual ICIEM Meeting
    10. Centers of Excellence Awards Presented to Over 100 Nursing Facilities as Nursing Facilities Reach the Tipping Point in Treating Pressure Ulcers
    11. CRF announces late breaking trials to be presented at TCT 2009 in San Francisco

    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/24/2009)... NCL Security Launches EyeCentral Remote Video P...rring Monthly Revenue for Central Stations and Sec...Texas (PRWEB) November 24, 2009 -- NCL Security La...curity Industry to Generate Recurring Monthly Reve...,"Integrated security systems has been and st...
    (Date:11/23/2009)... study by researchers from Virginia Commonwealth U...paired peroxisomal oxidation of polyunsaturated fa...n of nonalcoholic fatty liver (NAFL) to nonalcohol...significantly higher plasma monounsaturated fatty ... Full findings appear in the December issue of H...
    (Date:11/23/2009)... After suffering from women,s hair loss for almo...ck and she,s sharing her progress and the secret b...rough the release of her video diaries which inclu...ng her treatment. , (PRWe...ufferer Zsanett Siklosi has released the video dia...
    (Date:11/23/2009)...toTargetIndividualsintheRecommendedPriorityGroups ...e/--TheDepartmentofHealthannouncedtodaytheywillcon...ateHealthCentersinDelaware,Lancaster,andLehighcoun...ccinewillbeadministeredforfreetoindividualsinthere...othevaccine.Thedepartmentasksthatonlyindividualsin...
    (Date:11/23/2009)...h care professionals enjoy a pay raise for a job w...ves for health care performance may actually backf...re performance ratings for 25 medical groups acros...launch of a statewide pay-for-performance program ...s, productivity. , Reporting in the December ...
    Breaking Medicine News(10 mins):Health News:NCL Security Launches EyeCentral Video Platform for the Security Industry to Generate Recurring Monthly Revenue for Central Stations and Security Dealers 2Health News:Metobolomics uncovers key indicators of nonalcoholic fatty liver disease 2Health News:Women's Hair Loss Treatment Results Captured on Video to Inspire Others 2Health News:Women's Hair Loss Treatment Results Captured on Video to Inspire Others 3Health News:Pennsylvania Department of Health Announces Additional H1N1 Vaccination Clinics in Delaware, Lancaster, Lehigh Counties 2Health News:Medical 'pay for performance' programs help improve care -- but not always, study finds 2Health News:Medical 'pay for performance' programs help improve care -- but not always, study finds 3
    ...le control cream and a potent neurotoxin, used by ... product is derived form a bacteria, Clostridium b... really surprising to note that this form of neuro...e changes that underlie memory and learning, and p...
    ... vera extract is known for its therapeutic effect ...ore to it than just cosmetology applications. The ...ts and // vegetables in the future. A new fo...ot appear to affect food taste or appearance and s...
    ... increasing the drug resistance across the world. ... the journal The Lancet, worldwide resistance to d... by 12% since the mid-nineties. Adamantanes h...of resistance to amantadine and rimantadine among ...
    ...m, one of India's leading telecom companies, said ...hain Apollo Hospitals to provide telemedicine serv...ent, Apollo Hospitals will leverage Reliance Infoc... to the Apollo Telemedicine Networking Foundation ...
    ... the Technion-Israel Institute of Technology Sleep...gnosed with attention deficit hyperactivity disord...of drugs // to cure them of their problem. AD...ations (such as Ritalin) has been shown to be the ...
    ... period for branded Zidovudine in US has lead to a...ch would cost less and can be imported from other ...iral drug used in the // treatment of AIDS, the dr...r anti-retroviral drugs to combat HIV infection. G...
    Other Medicine News:Health News:Aloe Vera Coating For Fruits And Vegetables Preservation 2Health News:Children With ADHD May Just Be Sleepy 2
    (Date:11/23/2009)...ON,Pa.,Nov.23/PRNewswire/--BioTrendsResearchGroup,...eme report,thesecondinamulti-phasesyndicatedmarke...product,Feraheme,throughthefirstsixmonthsofproduct...veinformationfrom50uniqueNephrologistsandqualitati...anduseofFeraheme,obstaclestouse,reasonstouse,typic...
    (Date:11/23/2009)...IANAPOLIS,Nov.23/PRNewswire/--AMDLASERSannouncedth...aleducationbypartneringwithprestigiousindustry-lea...byAMDLASERS,willbetheexclusivesofttissuediodelaser...icharetargetedtothetop2%ofdentists. ,, (Photo: ...19 ) ,, "ItiswithgreatpleasurethatIproudlyannou...
    (Date:11/23/2009)...ATO,Calif.,Nov.23/PRNewswire-FirstCall/--RaptorPha...PTP )todayannouncedthepresentationofclinicaltriald...oid,AMPA/kainatereceptorantagonist,atthe12thIntern...opathicPain,heldonNovember20-21inSanFrancisco.Ther...linicalAnesthesiologyattheCenterforPainMedicineoft...
    Breaking Medicine Technology:Reported Use of AMAG's Feraheme (ferumoxytol) Continues To Be Low, But a Number of Nephrologists Are 'On the Verge' of Use 2AMD LASERS Announces New Partnership with Dr. Larry Rosenthal and Aesthetic Advantage 2Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain 2Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain 3Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain 4Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain 5MedShare and Qualicode Bring BlackBerry Mobile EMR to Quebec 58732 1MedShare and Qualicode Bring BlackBerry Mobile EMR to Quebec 58732 2MedShare and Qualicode Bring BlackBerry Mobile EMR to Quebec 58732 3U S Census Bureau Daily Feature for Oct 2 58730 1Ralphs Stores Giving Hope a Hand 28R 29 in October by Supporting Breast Cancer Awareness Initiatives 58728 1Ralphs Stores Giving Hope a Hand 28R 29 in October by Supporting Breast Cancer Awareness Initiatives 58728 2Ralphs Stores Giving Hope a Hand 28R 29 in October by Supporting Breast Cancer Awareness Initiatives 58728 3
    ...transfusions are a,valuable treatment mechanism in...nor disease transmission. Researchers are continua...rstand how certain diseases are,transmitted in an ...ns.,According to a study in sheep prepublished onl... Society of Hematology, the risk of transmitting,b...
    ...melphalan and prednisone arm demonstrated a, sign...omplete response -, CAMBRIDGE, Mass., Aug. 27 Mi...ced the publication of results from the 682,patien...ek,s edition of the,New England Journal of Medicin...it and a 30 percent complete remission (CR) rate w...
    Other Medicine Technology:Variant of Mad Cow Disease May Be Transmitted by Blood Transfusions, According to Animal Study 2Variant of Mad Cow Disease May Be Transmitted by Blood Transfusions, According to Animal Study 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 2New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 4New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 5New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 6
    ...nt-View LH Ovulation Predicting Test is a qualitat...zing Hormone (hLH) in human urine to predict the o...the elevation of human luteinizing hormone (hLH). ...hLH has a brief, significant rapid increase called...
    Shandon Manual Staining Station
    Shandon Finesse 315
    Shandon Histocentre 3 Embedding Center
    Medicine Products: